Biocon Biologics to acquire Viatris’ biosimilars business for $3.335 Bn

Date: 2022-02-28   Author: Pankaj Singh  Category: #news

Biocon Biologics to acquire Viatris’ biosimilars business for $3.335 Bn

Biocon Biologics has reportedly planned to acquire the biosimilars business of Viatris Inc for nearly USD 3.335 billion, which includes cash worth USD 2.335 billion along with preference shares.

The company will issue Viatris USD 1 billion worth of CCPS (compulsorily convertible preference shares). This translates to an equity stake of nearly 12.9% in the firm on a fully diluted basis.

In a statement, the Executive Chairperson of Biocon Biologics Kiran Mazumdar-Shaw expressed that the acquisition is revolutionary and will create a distinct, consolidated leading biosimilars enterprise of the world.

Mazumdar-Shaw added that the agreement will allow Biocon to achieve a strong commercial momentum in the developed markets of Europe and the United States and will expedite the company’s journey of developing a robust global brand.

She will continue to be Biocon Biologics’ Executive Chairperson whereas Viatris has appointed President Rajiv Malik to serve on the board of Biocon Biologics.

By consolidating the portfolio of Viatris, Biocon Biologics will possess one of the most extensive portfolios of commercialized biosimilars in the business. Biocon is anticipated to reap profits from Viatris’ biosimilars business. The move is predicted to upscale the biosimilars business of Biocon and enhance shareholder value.

Robert J Coury, the Executive Chairman of Viatris believes that this deal will enable the company to continue optimal participation in the global biosimilars sector while simultaneously expediting the company’s financial priorities.

After the closure of the deal, Biocon Biologics will realize the overall revenue and related profits from its collaborated products which will be a step forward from its current arrangement with Viatris.

It should be noted that Mylan is now part of Viatris, which was established with the merger of Mylan and Pfizer Inc’s Upjohn division.

Interestingly, Viatris partnered with more than 60 associations across the world in 2019 on issues of public health worldwide.

Source credit:

https://www.moneycontrol.com/news/business/mergers-acquisitions/biocons-arm-to-acquire-viatris-biosimilars-for-3-3-billion-8172261.html



About Author


Pankaj Singh linkdin-boxtwitter

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

Post Recommendents

Biotechnology Market by Development Analysis and Growth Progression to 2027

Author: Rahul Varpe

The Biotechnology Market report consists of information related to the projected CAGR of the global industry over the forecast period. Also, the numerous technological developments and innovations that are likely to drive the global market share o...


Joint Reconstruction Devices Market - Growth Potential & Opportunity Outlook to 2027

Author: Rahul Varpe

The Joint Reconstruction Devices Market research report is inclusive of general outline regarding the market and delivers knowledge about the basic market definitions as well as the numerous segmentations of the industry. The report further offers...


Electronic Health Record (EHR) Market by Drivers, Opportunities and Trends Analysis to 2027

Author: Rahul Varpe

The Electronic Health Record (EHR) Market report entails data about the anticipated CAGR to be encountered by the global industry over the analysis timeline. The study also enlists various technological advancements and product innovations which w...